Myeloproliferative Neoplasms | Specialty

Navigating Second-Line Treatment Decisions in Lower-Risk MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Dr Jain on Treatment Decision-Making With JAK Inhibitors in Myelofibrosis

October 13th 2025

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 10/5

October 12th 2025

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 9th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis

October 6th 2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

FDA Grants Priority Review to Orca-T for Hematologic Malignancies

October 6th 2025

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Dr Daver on Persisting Gaps in the Treatment of Relapsed/Refractory Higher-Risk MDS

October 3rd 2025

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Dr Mascarenhas on the Role of Imetelstat in the Myelofibrosis Treatment Paradigm

September 30th 2025

John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.

Ropeginterferon Alfa-2b Generates Superior Efficacy vs Anagrelide in High-Risk Essential Thrombocythemia

September 30th 2025

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Dr Kuykendall on the Relevance of QOL End Points in Myelofibrosis Clinical Trials

September 29th 2025

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R Myelofibrosis

September 26th 2025

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Real-World Data Show Hematologic Responses With Pacritinib in Myelofibrosis With Anemia

September 22nd 2025

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Dr Gangat on Ruxolitinib as the Standard of Care in Myelofibrosis

September 18th 2025

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.